During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology ***** e. He said:
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
9 days ago
